PD-1 Drug Stakes First-Line Claim in NSCLC (CME/CE)

(MedPage Today) -- Better survival, PFS, response rate compared with chemotherapy
via PD-1 Drug Stakes First-Line Claim in NSCLC (CME/CE)
by